1. Analyst View
2. Research Methodology
3. Introduction to CRISPR/Cas9 Genome Editing
4. Market Dynamics
4.1 Market Drivers
4.1.1 Expanding Drug Discovery Market
4.1.2 Surging Demand for Synthetic Genes
4.1.3 Rising Prevalence of Genetic Disorders
4.1.4 Increasing Investments
4.2 Market Challenges
4.2.1 Ethical Issues Concerning Misuse of CRISPR Gene Editing Tool
4.2.2 Presence of Alternative Gene Editing Tools
4.3 Market Opportunities
4.3.1 Increasing Usage of CRISPR Gene Editing for Gene Surgery
4.3.2 Enhancing Plant Immunity with CRISPR/Cas9
4.3.3 Emerging Contract Research Market for CRISPR/Cas9
5. Global CRISPR/Cas9 Market Outlook to 2022
6. CRISPR/Cas9 Market by Application
6.1 Cell Line Engineering
6.2 Genetic Engineering
6.3 CRISPR Plasmid
6.4 Gene Library
6.5 Human Stem Cells
6.6 Genetically Modified (GM) Organisms/Crops
7. CRISPR/Cas9 Market by End User
7.1 Academic & Research Institutes
7.2 Pharma/Biotech Companies
7.3 Others
8. CRISPR/Cas9 Market by Geography
8.1 North America
8.2 Europe
8.3 Asia Pacific
8.4 Rest of the World (RoW)
9. Mergers and Collaborations
10. Company Profiles
10.1 GE Healthcare
10.2 Thermo Fisher Scientific, Inc.
10.3 Agilent Technologies, Inc.
10.4 Lonza
10.5 GenScript
10.6 Horizon Discovery Group plc.
10.7 Editas Medicine, Inc.
10.8 CRISPR Therapeutics
10.9 Caribou Biosciences, Inc.
10.10 Intellia Therapeutics, Inc.
10.11 Integrated DNA Technologies
10.12 OriGene Technologies, Inc.
10.13 Transposagen Biopharmaceuticals, Inc.
10.14 New England Biolabs Inc.

List of Figures:

Figure 5-1: Global - CRISPR/Cas9 Market (Million US$), 2016-2022
Figure 6-1: Global - CRISPR/Cas9 Market by Application (%), 2016
Figure 7-1: Global - CRISPR/Cas9 Market by End User (%), 2016
Figure 8-1: Global - CRISPR/Cas9 Market by Geography (%), 2016
Figure 10-1: GE Healthcare - Revenue Breakup by Business Segments (%), 2015
Figure 10-2: GE Healthcare - Revenue Breakup by Geography (%), 2015
Figure 10-3: Thermo Fisher Scientific, Inc. - Revenue Breakup by Business Segments (%), 2015
Figure 10-4: Thermo Fisher Scientific, Inc. - Revenue Breakup by Geography (%), 2015
Figure 10-5: Agilent Technologies, Inc. - Revenue Breakup by Business Segments (%), 2015
Figure 10-6: Agilent Technologies, Inc. - Revenue Breakup by Product Category (%), 2015
Figure 10-7: Agilent Technologies, Inc. - Revenue Breakup by Geography (%), 2015
Figure 10-8: Lonza - Sales Breakup by Business Segments (%), 2015
Figure 10-9: GenScript - Revenue Breakup by Business Segments (%), 2015
Figure 10-10: GenScript - Revenue Breakup by Geography (%), 2015
Figure 10-11: Horizon Discovery Group plc, - Revenue Breakup by Business Segments (%), 2015
Figure 10-12: Horizon Discovery Group plc, - Revenue Breakup by Geography (%), 2015

List of Tables:

Table 10-1: GE Healthcare - Product Portfolio
Table 10-2: GE Healthcare - Key Financials (Million US$), 2013-2015
Table 10-3: Thermo Fisher Scientific, Inc. - Product Portfolio
Table 10-4: Thermo Fisher Scientific, Inc. - Key Financials (Million US$), 2013-2015
Table 10-5: Agilent Technologies, Inc. - Product Portfolio
Table 10-6: Agilent Technologies, Inc. - Key Financials (Million US$), 2013-2015
Table 10-7: Lonza - Technology Portfolio
Table 10-8: Lonza - Key Financials (Million US$), 2013-2015
Table 10-9: GenScript - Product & Technology Portfolio
Table 10-10: GenScript - Key Financials (Million US$), 2013-2015
Table 10-11: Horizon Discovery Group plc, - Product & Service Portfolio
Table 10-12: Horizon Discovery Group plc, - Key Financials (Million US$), 2013-2015
Table 10-13: Editas Medicine, Inc. - Product Pipeline
Table 10-14: Editas Medicine, Inc. - Key Financials (Million US$), 2013-2015
Table 10-15: CRISPR Therapeutics - Product Portfolio
Table 10-16: CRISPR Therapeutics - Product Pipeline
Table 10-17: Caribou Biosciences, Inc. - Product Portfolio
Table 10-18: Intellia Therapeutics - Product Portfolio
Table 10-19: Intellia Therapeutics - Product Pipeline
Table 10-20: Integrated DNA Technologies, Inc. - Product Portfolio
Table 10-21: OriGene Technologies, Inc. - Product Portfolio
Table 10-22: Transposagen Biopharmaceuticals, Inc. - Product Portfolio
Table 10-23: New England Biolabs Inc. - Product Portfolio